Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147.
      Google Scholar   
Citation:
J Clin Oncol vol 30 (15_suppl) 3514-3514
Meeting Instance:
ASCO 2012
Year:
2012
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2105  
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Bristol-Myers Squibb, ImClone, Sanofi-Aventis, and Pfizer.  
Grants:
NIH Grant CA 25224, NCI K05CA 142885  
Corr. Author:
 
Authors:
                 
Networks:
 
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: